John Pinching is an editor for PharmaTimes Media Ltd, specializing in the pharmaceutical industry. With a focus on providing up-to-date news and insights, John covers a wide range of topics including drug approvals, mergers and acquisitions, partnerships, and regulatory developments within the pharmaceutical sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United Kingdom (National)
Not enough data
John's coverage heavily focuses on healthcare and pharmaceutical industry, particularly press releases and data citations. He may prefer pitches with access to exclusive data or insights into the latest advancements in pharmaceuticals, medical treatments, clinical trials, mergers and acquisitions within the healthcare sector.
Given his extensive use of press releases as sources for his articles, he may be interested in receiving well-documented pitches with detailed information about newsworthy developments within the healthcare and pharmaceutical industries.
While John does not have a specific geographic focus mentioned, it is evident that his interest lies in global developments within the healthcare and pharmaceutical sectors. Therefore, he would likely appreciate relevant information from experts across different regions impacting these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Pinching
Real-world studies show effectiveness of mogamulizumab in routine practice
By: John Pinching
Teclistamab offers hope for patients exhausting treatment options
By: John Pinching
Sheffield cardiologists demonstrate cutting-edge TAVI procedure
By: John Pinching
Phase 2 study of TG4001 shows promise in cervical cancer patients
By: John Pinching
Partnership to harness AI for DUB-focused preclinical programmes
By: John Pinching
Study reveals potential new strategy for managing inflammatory bowel disease
By: John Pinching
CAL101 shows promising results and is set to enter phase 2 development
By: John Pinching
New treatment option for patients with newly diagnosed multiple myeloma
by | 23rd Oct 2024 | News CAL101 shows promising results and is set to enter phase 2 development
Walgreens Boots Alliance appoints Anthony Hemmerdinger as MD, UK and Ireland
(833) 317-6278 
